Hodgkin lymphoma: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CD20 2
• CD19 11
• PD-1 9
• CD30 9
• PD-L1 2
• BCL-2 2
• STAT3 0
• CD47 1
• JAK 1
• MYC 2
• TP53 0
• ALK 0
• BTK 1
• CD22 0
• IL-6 0
• AKT 0
• CTLA-4 0
• mTOR 0
• PI3K 0
• PRMT5 1
• ABL1 0
• BCMA 0
• CD123 1
• CD38 0
• EZH2 0
• METTL3 0
• NOTCH1 0
• NRF2 0
• TIM-3 0
• AMPK 0
• AXL 0
• BDNF 1
• CCR5 0
• CDK4/6 0
• CXCR4 0
• FGFR 0
• FLT3 0
• GLP-1 0
• HDAC 0
• IL-15 1
• IL-17 0
• MET 0
• MMP-9 0
• NLRP3 0
• PARP 0
• PRAME 0
• SGLT2 0
• SIRT1 0
• TERT 0
• TIGIT 0
• TLR4 0
• TNF 0

7 of 7+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R01

  Patient-Derived Models to Identify Effective Therapies in Aggressive Large B-Cell Lymphomas

  Massachusetts General Hospital· Boston, United States· US$600,075 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R43

  Preclinical development of novel dual EZH2-BRD4 inhibitor for EZH2-mutant lymphoma

  Biologica Llc· Charlotte, United States· US$385,056 awarded in fiscal year 2026· until Aug 2027

• NIH NCI · R01

  Integrating AI and Deep Mutational Scanning to Predict the Cancer-Promoting Effect of Shelterin Mutations

  University of California Berkeley· Berkeley, United States· US$2,197,943 awarded in fiscal year 2026· until Aug 2029

• NIH NCI · K08

  Improving fatigue and symptom assessment using patient-reported outcomes measures for patients with indolent non-Hodgkin lymphomas

  University of Colorado Denver· Aurora, United States· US$285,530 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R01

  Enhancing CAR-T cell therapy for DLBCL

  Washington University· Saint Louis, United States· US$548,528 awarded in fiscal year 2026· until Aug 2031

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  SMART-SMAPs: a new paradigm of cell-free cytotoxic immunotherapy for resistant CLL

  Universita Degli Studi di Siena· Siena, Italy· EU contribution €150,000· until Mar 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Investigating the Interplay of Natural Killer Cells and Microbiome in Non-Hodgkin's Lymphoma (LINK-M)

  Luxembourg Institute of Health· Strassen, Luxembourg· EU contribution €216,240· until Aug 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Integrated Assessment of Indoor Radon and Hazardous Air Pollutants in Non-Hodgkin Lymphoma – a Case-Control Study in a Radon-Prone Area (AlphaLymph)

  Universidad de Santiago de Compostela· Santiago De Compostela, Spain· EU contribution €242,593· until Feb 2029· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Studying the Microenvironment And Related Targets in Non-Hodgkin's Lymphoma (SMART-NHL)

  Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer· Barcelona, Spain· EU contribution €181,153· until Aug 2027

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Development and characterization of a novel CAR T-cell therapy for NHL (CARLY)

  Fundacio Institut de Recerca Contra la Leucemia Josep Carreras· Badalona, Spain· EU contribution €226,441· until Jun 2027

10 of 296 running projects, newest first. Listed amounts together: US$180.6m + €11.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

  NCT04540796· Janssen Research & Development, LLC· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 5
• Mendelian Randomization Analysis 6
• CRISPR-Cas Systems 1
• Gene Expression Profiling 14
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 5
• Metabolomics 1
• Flow Cytometry 9
• Immunohistochemistry 19
• Liquid Biopsy 1
• Circulating Tumor DNA 6
• Xenograft Model Antitumor Assays 20
• Positron-Emission Tomography 21
• Magnetic Resonance Imaging 18
• Machine Learning 11
• Deep Learning 3
• Cohort Studies 30
• Genome-Wide Association Study 7

• Association Between Oral Cavity Cancer and Lymphoma: A Bidirectional Mendelian Randomization Analysis.

  Oral Health Prev Dent, Aug 2026

• Local genetic correlations between systemic sclerosis and common cancer types.

  PLoS One, May 2026

• Unraveling the inflammatory bridge: genomic evidence identifies TNFRSF9 as a potential biomarker linking Sjögren's syndrome to total risk non-Hodgkin lymphoma.

  Clin Rheumatol, Apr 2026

• Multiple Sclerosis and Hematologic Malignancies: A Bidirectional Mendelian Randomization Study.

  J Vis Exp, Jan 2026

• Alcohol consumption and risk of cancer: a Mendelian randomization analysis of four biobanks and consortium data.

  BMC Med, Dec 2025

• Integrative multi-omics and Mendelian randomization identify WWOX and THBS2 as potential therapeutic targets in mature T/NK-cell lymphoma.

  J Transl Med, Nov 2025

• Causal association between circulating Klotho levels and B-cell lymphoma: A 2-sample Mendelian randomization study.

  Medicine (Baltimore), Oct 2025

See which targets of this disease your abstract mentions, and go to the people working on them.